Skip to main content
. 2020 Jul 1;35(4):834–853. doi: 10.3904/kjim.2020.204

Figure 1.

Figure 1.

Ongoing first-line phase III trials investigating immune checkpoint inhibitors in advanced urothelial cancer. UC, uorthelial carcinoma; PFS, progression-free survival; OS, overall survival; PD-L1, programmed death ligand-1; CPS, combined positive score.